Literature DB >> 8482449

Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.

R Lamberts1, W Creutzfeldt, H G Strüber, G Brunner, E Solcia.   

Abstract

BACKGROUND: The effects of chronic drug-induced hypergastrinemia on the exocrine and endocrine stomach are still incompletely understood. Chronic hypergastrinemia in rats and humans is associated with gastric argyrophil cell hyperplasia.
METHODS: Seventy-four patients with chronic ranitidine-resistant ulcerations were treated chronically with omeprazole (median observation period 48 [6-84] months).
RESULTS: Median fasting serum gastrin levels increased from a pretreatment value of 74-145 pg/mL after 3 months. No further increase was observed thereafter. The finding of atrophic gastritis increased from 1.8% to 20.8% after 5 years. A doubling of the mean argyrophil cell volume density (0.36% vs. 0.74% after 5 years; P < 0.01%) was paralleled by a decrease in the normal endocrine cell growth pattern from 64.3% to 33.3% and an increase in micronodular hyperplasia (8.9% vs. 16.7%). These changes correlated with the severity of corpus gastritis and seemed to be more disease- than drug-related. No statistically significant changes were observed in the antral G- and D-cell volume densities under therapy.
CONCLUSIONS: Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis. Because hypergastrinemia and gastritis are closely related, it is difficult to quantitatively assess their respective role in this process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482449     DOI: 10.1016/0016-5085(93)90344-c

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  69 in total

Review 1.  Topical review. Gastrin and gastric epithelial physiology.

Authors:  G J Dockray
Journal:  J Physiol       Date:  1999-07-15       Impact factor: 5.182

Review 2.  Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation.

Authors:  D McNamara; C O'Morain
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

3.  Keeping neuroendocrine cells in check: roles for TGFbeta, Smads, and menin?

Authors:  G J Dockray
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

Review 4.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

5.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

6.  Proton pump inhibitors and gastric neoplasia.

Authors:  E J Kuipers
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

7.  Gastric mucosal proliferative and total tyrosine kinases activities increase in Helicobacter pylori-induced chronic gastritis.

Authors:  Justyna Kotynia; Radzislaw Kordek; Alicja Kozlowska; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

8.  Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.

Authors:  R E Marshall; A Anggiansah; D K Manifold; W A Owen; W J Owen
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 9.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

10.  Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.

Authors:  K D Bardhan; P Cherian; A Vaishnavi; R B Jones; M Thompson; P Morris; A Brooks; J D'Silva; K R Gillon; C Wason; J Patterson; J Polak; A Bishop
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.